On 28 January 2021 NLS Pharmaceutics Ltd. priced its USD 20m IPO of 4,819,277 units with each unit consisting of one common share and one warrant to purchase one common share which are immediately separable from the units and issued separately. The common shares and the warrants have been approved for listing on the Nasdaq Capital Market under the symbols “NLSP” and “NLSPW”, respectively, and trading began on 29 January 2021. The offering closed on 2 February 2021. Headquarted in Stans, Switzerland, NLS Pharmaceutics Ltd. is a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders.